Cargando…

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

BACKGROUND: Multiple myeloma (MM) is a malignant plasma cell disease with a poor survival, characterized by the accumulation of myeloma cells (MMCs) within the bone marrow. Epigenetic modifications in MM are associated not only with cancer development and progression, but also with drug resistance....

Descripción completa

Detalles Bibliográficos
Autores principales:	Herviou, Laurie, Kassambara, Alboukadel, Boireau, Stéphanie, Robert, Nicolas, Requirand, Guilhem, Müller-Tidow, Carsten, Vincent, Laure, Seckinger, Anja, Goldschmidt, Hartmut, Cartron, Guillaume, Hose, Dirk, Cavalli, Giacomo, Moreaux, Jerome
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171329/ https://www.ncbi.nlm.nih.gov/pubmed/30285865 http://dx.doi.org/10.1186/s13148-018-0554-4

Ejemplares similares

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
por: Bruyer, Angelique, et al.
Publicado: (2018)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders
por: Jung, Yoo Jin, et al.
Publicado: (2021)

Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
por: Vikova, Veronika, et al.
Publicado: (2019)

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
por: Suzuki, Kazuhito, et al.
Publicado: (2023)

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma
por: Alaterre, Elina, et al.
Publicado: (2017)

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma
por: Hassen, Wafa, et al.
Publicado: (2014)

A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
por: Kopp, Katherine O., et al.
Publicado: (2023)

RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2021)

Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)
por: Liu, W M, et al.
Publicado: (2009)

309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations
por: Davis, Lorraine, et al.
Publicado: (2022)

Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma
por: Lien, I-Chia, et al.
Publicado: (2014)

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner
por: Dimopoulos, Konstantinos, et al.
Publicado: (2017)

Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma
por: Kassambara, Alboukadel, et al.
Publicado: (2012)

Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells
por: Kassambara, Alboukadel, et al.
Publicado: (2013)

Kinome expression profiling to target new therapeutic avenues in multiple myeloma
por: de Boussac, Hugues, et al.
Publicado: (2020)

Comprehensive characterization of the epigenetic landscape in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2022)

Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them
por: Cippitelli, Marco, et al.
Publicado: (2021)

IMiDs induce FAM83F degradation via an interaction with CK1α to attenuate Wnt signalling
por: Dunbar, Karen, et al.
Publicado: (2020)

RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators
por: Kassambara, Alboukadel, et al.
Publicado: (2021)

An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy
por: Szablewski, Vanessa, et al.
Publicado: (2018)

Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
por: Bartlett, J B, et al.
Publicado: (2005)

Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide
por: Furihata, Hirotake, et al.
Publicado: (2020)

A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy
por: Kassambara, Alboukadel, et al.
Publicado: (2014)

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

EZH2 in normal hematopoiesis and hematological malignancies
por: Herviou, Laurie, et al.
Publicado: (2015)

IMiDs Augment CD3-Bispecific Antibody–Induced CD8(+) T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production
por: Li, Ji, et al.
Publicado: (2023)

Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF
por: Corti, Angelo, et al.
Publicado: (2010)

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
por: Fionda, Cinzia, et al.
Publicado: (2015)

RECQ helicases are deregulated in hematological malignancies in association with a prognostic value
por: Viziteu, Elena, et al.
Publicado: (2016)

Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact
por: Devin, Julie, et al.
Publicado: (2019)

An IMiD-induced SALL4 degron system for selective degradation of target proteins
por: Yamanaka, Satoshi, et al.
Publicado: (2020)

IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform
por: Harama, Daisuke, et al.
Publicado: (2021)

Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?
por: Sponaas, Anne Marit, et al.
Publicado: (2021)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma
por: Viziteu, Elena, et al.
Publicado: (2016)

The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors
por: Abruzzese, Maria Pia, et al.
Publicado: (2019)

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo
por: Yu, Tengteng, et al.
Publicado: (2020)

iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
por: Bouguenina, Habib, et al.
Publicado: (2023)

The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma
por: Heider, Michael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dch3nogclv02f4cr8nclr7hhs6